Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study.

"Declaration of personal interests : PL has participated in advisory boards/speaker bureaux for AbbVie, Alnylam, Arrowhead, Bristol‐Myers Squibb, Eiger, Gilead Sciences, Janssen, MYR Pharmaceuticals, MSD and Roche. TB has received research support from AbbVie, Bristol‐Myers Squibb, Gilead, Intercept, Janssen, Merck/MSD, Novartis, Pfizer, Roche and Sequana Medical; and provided consultancy, and participated in speakers bureaux and advisory boards for AbbVie, Alexion, Bayer, Boehringer Ingelheim, Bristol‐Myers Squibb, Gilead, GlaxoSmithKline, Intercept, Janssen, Merck/MSD, Merz, Novartis, Sequana Medical and Roche. MB has received grants from Gilead Sciences and lecture sponsorship from AbbVie, Gilead Sciences and Merck. AP has acted as a consultant for AbbVie and received lecture sponsorship from AbbVie, Bristol‐Myers Squibb and Gilead Sciences. JP has received grants or research support from Bristol‐Myers Squibb, Novartis and Roche; acted as a consultant/advisor for Abbott, AbbVie, Bristol‐Myers Squibb, Boehringer Ingelheim, Gilead Sciences, GlaxoSmithKline, Janssen, Kedrion, Merck, MSD, Novartis and Roche; and acted as a speaker for Abbott, Bristol‐Myers Squibb, Boehringer Ingelheim, Gilead, Janssen, Kedrion, MSD, Novartis and Roche. SDR has participated in advisory boards and acted as a paid speaker for AbbVie, Gilead and MSD. FZ has received grants from Evotec and Roche, and acted as a consultant for AbbVie, Arbutus, Gilead, Janssen, MYR Pharma, Roche, Springbank, Transgene, and Vir Biotech. IB, JFF, BJ, MOB, AvT and HR are employees and stockholders of Gilead Sciences."

"We thank all patients and the full ReCoRd investigator group involved in the study. Participating investigators were: in France, M. Bourlière, V. De Ledinghen, G. Riachi, F. Zoulim, V. Loustaud‐Ratti, A. Tran, D. Larrey, J. Dumortier, V. Leroy, S. Metivier, P. Sellier; in Germany, S. Mauss, J. Peterson, T. Berg, I. Schiefke, C. Niederau, G. Teuber, T. Goeser, M. C. Jung, A. Grambihler, A. Pathil‐Warth, K. Sprinzl, M. Von der Ohe, C. Antoni, K. Weigand; in Italy, P. Andreone, P. Lampertico, V. Di Marco, S. Madonia, M. Puoti, T. Santantonio, M. Vigano, A. Ciancio, G. D'Offizi, M. Pirisi; in Spain, M. Buti, E. Suarez Garcia, J. M. Pascasio Acevedo, R. Andrade, F. Gea, M. A. Serra Desfilis, E. Molina Perez, M. Manzano Alonso, J. A. Carrion, S. Aoufi Rabih, M. M. Planas; in the UK, S. Ryder, K. Agarwal, A. Ustianowski, R. Aspinall, P. Kennedy, A. M. Geretti, R. McCorry, M. Foxton, B. Healy. Medical writing support, including development of drafts in consultation with the authors, assembling tables and figures, collating author comments, copyediting, fact checking and referencing, was provided by Beatrice Tyrrell, DPhil at Aspire Scientific (Bollington, UK) and funded by Gilead Sciences Europe Ltd (Uxbridge, UK). Gilead Sciences Europe Ltd (Uxbridge, UK) designed and funded the study and was involved in the collection, analysis and interpretation of data, as well as reviewing drafts and the final manuscript. The final decision to submit the article for publication was solely that of the authors."

"The study was conducted in accordance with the International Conference on Harmonisation E2E guidelines, the Guidelines for Good Pharmacoepidemiology Practices and EU Good Pharmacovigilance Practices. Participating centres adhered to any additional local ethical approval requirements. Since patient information was de‐identified, informed consent was not obtained unless required by local ethics committees or by country National Data Protection Laws for participating centres. The study is registered with the EU PAS Register: EUPAS12897."